Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Literature DB >> 2191821

Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Abstract

Part I of this article, which appeared in the previous issue of the Journal, covered the physical properties, pharmacology, toxicology and pharmacokinetics of furosemide (frusemide). In part II the authors examine the pharmacodynamics of the drug, and suggest various areas for future study.

Entities: Chemical

Mesh：

Substances：
Furosemide

Year: 1990 PMID： 2191821 DOI： 10.2165/00003088-199018060-00003

Source DB: PubMed Journal: Clin Pharmacokinet ISSN： 0312-5963 Impact factor: 6.447

154 in total

1. A simplified assay of furosemide in plasma and urine by high-pressure liquid chromatography.

Authors: K Carr; A Rane; J C Frölich
Journal: J Chromatogr Date: 1978-05-01

2. Pharmacokinetics and pharmacodynamics of high dose furosemide in patients with chronic renal failure or nephrotic syndrome.

Authors: H J Kühnel; K Günther; G Stein; A Hoffmann-Traeger
Journal: Int J Clin Pharmacol Ther Toxicol Date: 1987-11

3. Pharmacokinetics of orally administered furosemide.

Authors: M R Kelly; R E Cutler; A W Forrey; B M Kimpel
Journal: Clin Pharmacol Ther Date: 1974-02 Impact factor: 6.875

4. The dose-response characteristics of the acute non-diuretic peripheral vascular effects of frusemide in normal subjects.

Authors: G D Johnston; D P Nicholls; W J Leahey
Journal: Br J Clin Pharmacol Date: 1984-07 Impact factor: 4.335

5. Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor.

Authors: A Rakhit; G M Kochak; V Tipnis; M E Hurley
Journal: Clin Pharmacol Ther Date: 1987-05 Impact factor: 6.875

6. Specimen handling and high-performance liquid chromatographic determination of furosemide.

Authors: A L Kerremans; Y Tan; C A Van Ginneken; F W Gribnau
Journal: J Chromatogr Date: 1982-04-16

7. Furosemide kinetics in renal failure.

Authors: W J Tilstone; A Fine
Journal: Clin Pharmacol Ther Date: 1978-06 Impact factor: 6.875

8. Disposition and absolute bioavailability of furosemide in healthy males.

Authors: E S Waller; S F Hamilton; J W Massarella; M A Sharanevych; R V Smith; G J Yakatan; J T Doluisio
Journal: J Pharm Sci Date: 1982-10 Impact factor: 3.534

9. Furosemide disposition in cirrhosis.

Authors: R K Verbeeck; R V Patwardhan; J P Villeneuve; G R Wilkinson; R A Branch
Journal: Clin Pharmacol Ther Date: 1982-06 Impact factor: 6.875

10. Biotransformation of furosemide in kidney transplant patients.

Authors: D E Smith; L Z Benet
Journal: Eur J Clin Pharmacol Date: 1983 Impact factor: 2.953

14 in total

1. Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors: Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal: Pharm Res Date: 2004-01 Impact factor: 4.200

2. Section 3: Prevention and Treatment of AKI.

Authors:
Journal: Kidney Int Suppl (2011) Date: 2012-03

3. The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit.

Authors: V Pichette; D Geadah; P du Souich
Journal: Br J Pharmacol Date: 1996-11 Impact factor: 8.739

4. Humanized thymidine kinase-NOG mice can be used to identify drugs that cause animal-specific hepatotoxicity: a case study with furosemide.

Authors: Dan Xu; Sara A Michie; Ming Zheng; Saori Takeda; Manhong Wu; Gary Peltz
Journal: J Pharmacol Exp Ther Date: 2015-05-11 Impact factor: 4.030